Conference Abstract | Volume 9 (ConfPro8): Abstract 58 | Published: 09 Oct 2026
Ninyen Paul1,&, Ambrose Ereyong Naah1 , Mavis Cecilia Coffie1, Charles Noora Lwanga1, Donne Ameme1, Delia Bandoh1, Samuel Oko Sackey1, Basil Benduri Kaburi1, Joseph Asamoah Frimpong1, Ernest Kenu1, Jonathan Avuyitor1, John Baffoe1, Faiza Alhassan1, Phyllis Flescher1, Kingsley Amoako1, Solomon Boakye Mensah2, Kojo Boateng3, Mark Kwasi Kyei-Baffour3
1Ghana Field Epidemiology and Laboratory Training Programme, School of Public Health, University of Ghana, Accra, Ghana, 2Ashanti Regional Health Directorate, Kumasi, Ghana, 3Ejura Municipal Health Directorate
&Corresponding author: Ninyen Paul, Ghana Field Epidemiology and Laboratory Training Programme, University of Ghana School of Public Health, Accra, Ghana, Email: Ninyen27@gmail.com, ORCID: https://orcid.org/0009-0001-4062-1210
Received: 11 Mar 2026, Accepted: 30 Aug 2026, Published: 09 Oct 2026
Domain: Infectious Disease Epidemiology
Keywords: Yellow fever, surveillance; arboviral hemorrhagic fever, targeted risk communication, line-list
©Ninyen Paul et al. Journal of Interventional Epidemiology and Public Health (ISSN: 2664-2824). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cite this article: Ninyen Paul et al., Yellow Fever surveillance data analysis, Ashanti Region, Ghana, 2025. Journal of Interventional Epidemiology and Public Health. 2026;9(ConfPro8):58. https://doi.org/10.37432/JIEPH-CONFPRO8-0058
Yellow fever is a vaccine-preventable arboviral hemorrhagic disease that remains a threat in West Africa. In 2021, Ghana reported a major outbreak in its northern and middle belts, with a 50% case fatality rate. We aimed to describe the distribution of yellow fever, determine temporal and seasonal trends, identify factors associated with laboratory confirmation, and assess the association between vaccination status and severe disease outcomes among confirmed yellow fever cases in the Ashanti Region from 2019 to 2024.
We conducted a secondary analysis of yellow fever SORMAS line-list data for the Ashanti Region from 2019 to 2024. We summarized distributions by person, place, and time using frequencies, proportions, and epidemic-month trends. Crude odds ratios were estimated from 2×2 tables using Fisher’s exact tests. We used multivariable logistic regression to estimate adjusted odds ratios for factors associated with laboratory confirmation.
We analyzed 837 records; 27 were laboratory-confirmed, yielding a confirmation rate of 3.2%. The median age was 14 years (IQR: 5–26 years). Suspected reports rose from 66 in 2019 to 198 in 2024, and 23 of 27 confirmed cases were reported in 2024. In the adjusted analysis, reporting in 2024 was strongly associated with laboratory confirmation compared with 2019–2023 (aOR 29.94, 95% CI 9.20–97.46; p<0.001). Reporting during July–October was also independently associated with confirmation (aOR 6.27, 95% CI 2.48–15.85; p<0.001). No deaths, hemorrhagic syndrome, or bleeding/bruising were recorded among confirmed cases.
Yellow fever surveillance in the Ashanti Region showed an increase in suspected case reports, with a marked temporal and seasonal signal in 2024, particularly during July–October. Public health priorities include pre-season preparedness, district-level active surveillance, verification of vaccination status, targeted risk communication in districts with confirmed cases or a high suspected burden, improved data completeness, and rapid reconciliation of laboratory results.
Menu